Announcement on Subsidiary Obtaining Notice of Approval for Drug Clinical Trials
Release time:
2021-05-20
Securities Code: 600668 Securities Abbreviation: Jianfeng Group No: pro 2021-001
Zhejiang Jianfeng Group Co., Ltd.
Announcement on Subsidiaries Obtaining Drug Clinical Trial Approval Notice
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assumes individual and joint responsibility for the truthfulness, accuracy and completeness of its contents .
Important Note:
- Company's approval notice for drug clinical trials will not have a significant impact on the company's recent operating results.
- Risk Warning: Due to the particularity of drug research and development, the pre-development of drugs and the long cycle and many links of products from development, clinical trials to production are susceptible to some uncertain factors, clinical trial progress, There are many uncertainties in the results and the future product market competition situation.
1. Summary
Recently, Zhejiang Erying Pharmaceutical Co., Ltd. (hereinafter referred to as "Erying Company") and , the controlling subsidiary of Zhejiang Jianfeng Pharmaceutical Co., Ltd., the controlling subsidiary of the Company, received the Notice of Approval for Clinical Trials of Drugs approved and issued by the State Drug Administration. The relevant details are hereby announced as follows:
2. drug basic information content
drug name: acetaminophen suppository
English name: Paracetamol Suppositories
dosage form: suppository
application classification: generic drug application
specification: 75mg , 125mg
registration classification: chemical drugs category 3
applicant: Zhejiang erying drug co., ltd.
approval conclusion: "according to the the People's Republic of China drug administration law and relevant regulations, after examination, the acetaminophen suppository accepted on 2020 5 February 13 meets the relevant requirements for drug registration, it is recommended that the bioequivalence study of this product be carried out in healthy adults with a single fasting dose, and that the study of BE be exempted under different specifications to meet pharmaceutical requirements."
3. Drug Research and Development and Investment
Acetaminophen Suppository is an antipyretic analgesic developed by Erying Company. Its registered classification belongs to chemical drug 3 . Acetaminophen Suppository is indicated for fever caused by common cold or influenza in children, and is also used for relieving mild to moderate pain such as headache, arthralgia, migraine, toothache, myalgia and neuralgia. As of the date of this announcement, the accumulated research and development expenses and technical investment of the project totaled about RMB ,788.09 . Market Situation of
4. Similar Drugs
Acetaminophen Suppository was first developed by German Bene Company and listed in Germany in 1960 . In 2019 , the dosage of German acetaminophen Suppository was about 1.08 .6 billion tablets (data source: IMS ). At present, paracetamol suppositories of infant specifications have been listed in many countries in the world. At present, paracetamol suppositories of 125 mg , 150 mg , 300 mg and 600 mg have been listed in China, of which 125 mg and 150 mg are used for fever caused by common cold or influenza in children aged 1-6 , no paracetamol suppositories exist for infants and young children aged 0-1 years. Acetaminophen suppository (75 mg ) developed by Erying Company is suitable for antipyretic and analgesic treatment for infants aged 0-1 years old in China. Acetaminophen suppository (125 mg ) is suitable for infants aged 6 months to 2 years old (administered according to age and weight). Scientifically administered acetaminophen suppository will be provided for infants aged 0-2-2-116 years old. Approval Procedures to Be Performed for Listing of 5. Products
Er Ying Company will conduct clinical trials (bioequivalence studies) according to the requirements of the Notice of Approval of Drug Clinical Trials. After the clinical trials are completed, it will apply for production. After passing the review and approval of the State Food and Drug Administration and obtaining the approval documents for drug production, it can produce
products and go on sale. 6. Impact on Listed Companies and Risk Tips
The company's approval notice for drug clinical trials will not have a significant impact on the company's recent operating results. Due to the particularity of drug research and development, the pre-development of drugs and the long cycle and many links from development, clinical trials to production of products are easily affected by some uncertain factors. There are many uncertainties in the progress and results of clinical trials and the future product market competition situation. The company will be based on the progress of research and development in a timely manner to fulfill the obligations of information disclosure, so that the majority of investors pay attention to investment risks.
hereby announce
Zhejiang Jianfeng Group Co., Ltd. Board of Directors
January 6, 2001
More information
Daye Peak Launches Anti-"Three Violations" Special Activities
Recently, Daye Jianfeng Cement Company has set up a special leading group for "anti-three violations" activities headed by Zhang Fengliang, deputy general manager of the group company and general manager of Daye Jianfeng, to vigorously carry out anti-"three violations" activities throughout the plant. Most safety accidents come from illegal command, illegal operation and violation of labor discipline. In order to reduce or even put an end to the phenomenon of "three violations", eradicate persistent diseases in violation of rules and regulations, eliminate hidden dangers of accidents, standardize employees' production safety behavior, and prevent the occurrence of all kinds of production safety accidents, Daye Peak has carried out special activities against "three violations" according to the requirements of the implementation plan of "anti-three violations, accident prevention and safety protection" carried out by the Safety Committee of Baoan Town. The purpose is to strengthen employees' understanding of the harmfulness, make safety education and training more targeted, make the implementation of safety rules and regulations more in place, improve employees' awareness of safety production and safety skills, avoid personal injury accidents, misoperation accidents and other liability accidents caused by violations, and effectively achieve safety production standardization Anti-violation, procedural accident prevention, standardization to ensure safety, and fully achieve the 2016 safety production work goal. According to the plan, this activity is divided into three stages: the first stage is from September 1 to September 15, which is the mobilization and deployment stage; the second stage is from September 16 to October 15, which is the implementation stage; the third stage is from October 16 to October 20, which is the summary and improvement stage. The activities mainly carried out self-examination of "anti-three violations" by hanging safety slogans and banners, and organized the study of safety regulations such as "100 typical violations of production safety" and "post safety operation procedures".
2020
07-31
Daye Peak Launches Anti-"Three Violations" Special Activities
Recently, Daye Jianfeng Cement Company has set up a special leading group for "anti-three violations" activities headed by Zhang Fengliang, deputy general manager of the group company and general manager of Daye Jianfeng, to vigorously carry out anti-"three violations" activities throughout the plant. Most safety accidents come from illegal command, illegal operation and violation of labor discipline. In order to reduce or even put an end to the phenomenon of "three violations", eradicate persistent diseases in violation of rules and regulations, eliminate hidden dangers of accidents, standardize employees' production safety behavior, and prevent the occurrence of all kinds of production safety accidents, Daye Peak has carried out special activities against "three violations" according to the requirements of the implementation plan of "anti-three violations, accident prevention and safety protection" carried out by the Safety Committee of Baoan Town. The purpose is to strengthen employees' understanding of the harmfulness, make safety education and training more targeted, make the implementation of safety rules and regulations more in place, improve employees' awareness of safety production and safety skills, avoid personal injury accidents, misoperation accidents and other liability accidents caused by violations, and effectively achieve safety production standardization Anti-violation, procedural accident prevention, standardization to ensure safety, and fully achieve the 2016 safety production work goal. According to the plan, this activity is divided into three stages: the first stage is from September 1 to September 15, which is the mobilization and deployment stage; the second stage is from September 16 to October 15, which is the implementation stage; the third stage is from October 16 to October 20, which is the summary and improvement stage. The activities mainly carried out self-examination of "anti-three violations" by hanging safety slogans and banners, and organized the study of safety regulations such as "100 typical violations of production safety" and "post safety operation procedures".
2020
07-31
The water and soil conservation scheme of Daye Peak Mine passed the review.
The water and soil conservation plan of Jinshan limestone mine and Baiyunsi sand shale mine of Daye Peak Cement Company passed expert review a few days ago. In order to effectively prevent and control soil erosion, protect and rationally utilize water and soil resources, reduce water, drought, wind and sand disasters, and improve the ecological environment, in accordance with the "the People's Republic of China Soil and Water Conservation Law", "Management Measures for Soil and Water Conservation Programs for Development and Construction Projects" and other laws and regulations Relevant technical specifications and the requirements of local management departments, Daye Peak commissioned Daye City Soil and Water Conservation Test Station in May this year to prepare soil and water and soil and soil conservation plans for Jinshan limestone mine. Recently, the water and soil conservation plans of the two mines have been prepared and reviewed by experts. After nearly a day of careful review, the participating experts and leaders gave a high evaluation of the plan, and put forward some suggestions and opinions for improvement. At the same time, they fully affirmed Daye Peak's attitude of attaching great importance to the work of soil and water conservation in the mine, and unanimously agreed that the above two The plan passed the review. The service life of water and soil conservation scheme of Jinshan Limestone Mine and Baiyunsi Sand Shale Mine is 5 years. In the next five years, Daye Peak will entrust water and soil conservation supervision and monitoring, and gradually organize the implementation of prevention and control measures in accordance with the plan. By 2021, Daye Peak will prepare a technical evaluation report based on the implementation of the water and soil conservation plan, check the construction and implementation of responsibilities, evaluate the effect of soil erosion prevention and control, and apply for completion acceptance. (Daye Peak)
2020
07-31
Daye Peak Launches Anti-"Three Violations" Special Activities
Recently, Daye Jianfeng Cement Company has set up a special leading group for "anti-three violations" activities headed by Zhang Fengliang, deputy general manager of the group company and general manager of Daye Jianfeng, to vigorously carry out anti-"three violations" activities throughout the plant. Most safety accidents come from illegal command, illegal operation and violation of labor discipline. In order to reduce or even put an end to the phenomenon of "three violations", eradicate persistent diseases in violation of rules and regulations, eliminate hidden dangers of accidents, standardize employees' production safety behavior, and prevent the occurrence of all kinds of production safety accidents, Daye Peak has carried out special activities against "three violations" according to the requirements of the implementation plan of "anti-three violations, accident prevention and safety protection" carried out by the Safety Committee of Baoan Town. The purpose is to strengthen employees' understanding of the harmfulness, make safety education and training more targeted, make the implementation of safety rules and regulations more in place, improve employees' awareness of safety production and safety skills, avoid personal injury accidents, misoperation accidents and other liability accidents caused by violations, and effectively achieve safety production standardization Anti-violation, procedural accident prevention, standardization to ensure safety, and fully achieve the 2016 safety production work goal. According to the plan, this activity is divided into three stages: the first stage is from September 1 to September 15, which is the mobilization and deployment stage; the second stage is from September 16 to October 15, which is the implementation stage; the third stage is from October 16 to October 20, which is the summary and improvement stage. The activities mainly carried out self-examination of "anti-three violations" by hanging safety slogans and banners, and organized the study of safety regulations such as "100 typical violations of production safety" and "post safety operation procedures".
2020
07-30
Spike Pharmaceuticals Enters Infant Drug Market
Jindal Baby Drug Co., Ltd. Established Peak Pharmaceuticals to Enter Infant Drug Market Recently, Zhejiang Jindal Baby Drug Co., Ltd., a Sino-German joint venture controlled by Peak Pharmaceuticals, completed registration. Peak Pharmaceuticals will use this as a basis to introduce German technology and products and develop the infant drug market. Zhejiang Jindel Baby Drug Co., Ltd. was jointly funded by Jianfeng Pharmaceutical, Germany Gefu Pharmaceutical Co., Ltd. and Zhuhai Hengqin Deyunjia International Trade Co., Ltd., with a registered capital of 20 million yuan, of which Jianfeng Pharmaceutical contributed 11 million yuan in cash, accounting for 55% of the registered capital. Gefu Pharmaceuticals invested 5 million yuan in the evaluation of two proprietary technologies of "diazepam suppository" and "acetaminophen suppository, 25% of the registered capital; De Yunjia contributed 4 million yuan in cash, accounting for 20% of the registered capital. The company's registered address is in Jinxi Development Zone, Jinhua City. It will rent the existing factory building of Jianfeng Pharmaceutical Jinxi Pharmaceutical Factory for renovation, and strive to absorb their respective expertise and adopt appropriate advanced technology and scientific management methods. A modern pharmaceutical enterprise focusing on the research and development, production and sales of pharmaceutical preparations for infants and children. In this cooperation, the corresponding products of "diazepam suppository" and "acetaminophen suppository", which Ge Fu pharmaceutical has invested in with proprietary technology evaluation, have been listed in Germany, among which diazepam suppository is a therapeutic drug for anti-anxiety, sleep disorder and muscle tension increase; acetaminophen is used for fever caused by cold or cold, and also for relieving mild to moderate pain. After the establishment of the joint venture company, it will be based on these two know-how.
2020
07-31
Jinhua City People's Congress Leaders Peak Survey
On July 26, Cai Jian, deputy director of the Jinhua Municipal People's Congress, Chen Zhishi, secretary general of the Standing Committee of the National People's Congress, and a group of four people visited Jianfeng to conduct research on the introduction of talents and technological innovation, and to communicate with Jiang Xiaomeng, Yu Jianhong, Huang Jinlong, Xiang Chongping, Lan Xiaolong and other group company leaders conducted in-depth exchanges. (this newspaper reporter)
2020
07-31